These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 30065271)

  • 1. Investigating pediatric disorders with induced pluripotent stem cells.
    Durbin MD; Cadar AG; Chun YW; Hong CC
    Pediatr Res; 2018 Oct; 84(4):499-508. PubMed ID: 30065271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology.
    Easley CA
    Methods Mol Biol; 2019; 1965():19-34. PubMed ID: 31069666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering personalized neural tissue by combining induced pluripotent stem cells with fibrin scaffolds.
    Montgomery A; Wong A; Gabers N; Willerth SM
    Biomater Sci; 2015 Feb; 3(2):401-13. PubMed ID: 26218131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem Cells: The Game Changers of Human Cardiac Disease Modelling and Regenerative Medicine.
    Parrotta EI; Scalise S; Scaramuzzino L; Cuda G
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31744081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
    Chhabra A
    Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.
    Cerneckis J; Cai H; Shi Y
    Signal Transduct Target Ther; 2024 Apr; 9(1):112. PubMed ID: 38670977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in reprogramming-based study of neurologic disorders.
    Nityanandam A; Baldwin KK
    Stem Cells Dev; 2015 Jun; 24(11):1265-83. PubMed ID: 25749371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis.
    Lichner Z; Mac-Way F; Yousef GM
    Eur Urol Focus; 2019 Mar; 5(2):250-261. PubMed ID: 28847686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells.
    Hu C; Li L
    Regen Med; 2016 Jan; 11(1):105-32. PubMed ID: 26679838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomaterial aided differentiation and maturation of induced pluripotent stem cells.
    Velmurugan BK; Bharathi Priya L; Poornima P; Lee LJ; Baskaran R
    J Cell Physiol; 2019 Jun; 234(6):8443-8454. PubMed ID: 30565686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling blood diseases with human induced pluripotent stem cells.
    Georgomanoli M; Papapetrou EP
    Dis Model Mech; 2019 Jun; 12(6):. PubMed ID: 31171568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived induced pluripotent stem cells in cancer research and precision oncology.
    Papapetrou EP
    Nat Med; 2016 Dec; 22(12):1392-1401. PubMed ID: 27923030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.
    Menon S; Shailendra S; Renda A; Longaker M; Quarto N
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell contributions to neurological disease modeling and personalized medicine.
    Liang N; Trujillo CA; Negraes PD; Muotri AR; Lameu C; Ulrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt A):54-62. PubMed ID: 28576415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine.
    Skalova S; Svadlakova T; Shaikh Qureshi WM; Dev K; Mokry J
    Int J Mol Sci; 2015 Feb; 16(2):4043-67. PubMed ID: 25689424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large Animal Models for the Clinical Application of Human Induced Pluripotent Stem Cells.
    Cong X; Zhang SM; Ellis MW; Luo J
    Stem Cells Dev; 2019 Oct; 28(19):1288-1298. PubMed ID: 31359827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cells and their implication for regenerative medicine.
    Csobonyeiova M; Polak S; Koller J; Danisovic L
    Cell Tissue Bank; 2015 Jun; 16(2):171-80. PubMed ID: 25037593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.
    Chun YW; Durbin MD; Hong CC
    Curr Cardiol Rep; 2018 Apr; 20(6):38. PubMed ID: 29666931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.